Sue A. Skull

Perth, WA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.

Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.

Journal: PLoS medicine

Published: March 06, 2024

Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.

Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.

Journal: International journal of pediatric otorhinolaryngology

Published: September 01, 2023

Can Research Training be Improved in Health Professional Student Curricula? A Qualitative Descriptive Study of Health Students' Experiences with an Integrated Research Training Platform.

Can Research Training be Improved in Health Professional Student Curricula? A Qualitative Descriptive Study of Health Students' Experiences with an Integrated Research Training Platform.

Journal: Medical science educator

Published: November 07, 2022

Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.

Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.

Journal: The Lancet. Infectious diseases

Published: February 14, 2022

Clinician and Caregiver Experience of Telehealth During COVID-19 Pandemic Supports Future Use.

Clinician and Caregiver Experience of Telehealth During COVID-19 Pandemic Supports Future Use.

Journal: Journal of paediatrics and child health

Published: October 27, 2021

Positive impacts of a dedicated General Paediatrics "home" ward in a tertiary paediatric Australian hospital.

Positive impacts of a dedicated General Paediatrics "home" ward in a tertiary paediatric Australian hospital.

Journal: Journal of paediatrics and child health

Published: July 08, 2020

Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.

Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.

Journal: Vaccine: X

Published: July 06, 2020

Embedding clinical audit into everyday practice: Essential methodology for all clinicians.

Embedding clinical audit into everyday practice: Essential methodology for all clinicians.

Journal: Journal of paediatrics and child health

Published: June 25, 2020

Repeat pneumococcal polysaccharide vaccination does not impair functional immune responses among Indigenous Australians.

Repeat pneumococcal polysaccharide vaccination does not impair functional immune responses among Indigenous Australians.

Journal: Clinical & translational immunology

Published: August 10, 2017

Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness.

Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness.

Journal: Vaccine

Published: October 06, 2016

Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial.

Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial.

Journal: BMJ open

Published: January 18, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026